Optum Rx operating earnings rise 10.9% as prescriptions fall
Optum Rx’s third-quarter operating earnings rose to $1.72 billion and its margin expanded to 4.3%, despite a 5.1% decline in adjusted prescriptions to 393 million. Revenue edged up to $39.9 billion. Biosimilar adoption, specialty pharmacy growth and operating efficiencies supported profitability, while membership attrition and pharmacy pricing changes could limit future growth.
UnitedHealth raises 2026 adjusted EPS guidance to at least $20.50
UnitedHealth reported third-quarter adjusted EPS of $4.69, while its medical care ratio improved to 88.4%. Operating earnings increased, though revenue was nearly flat and membership declined. The company raised its 2026 adjusted EPS outlook to at least $20.50, its third increase this year, and reiterated a long-term annual earnings growth target of 13% to 16%.
Morgan Stanley raises UnitedHealth price target to $531
Of 26 analysts, 18 rate UnitedHealth Strong Buy, three Moderate Buy and five Hold, while Strong Buy ratings have declined from 20 three months earlier. Morgan Stanley maintained its Buy rating and raised its price target to $531; the average target of $474.08 implies 17.7% upside. The article also noted the company’s third-quarter results and higher 2026 adjusted earnings outlook.
UnitedHealthcare drops Medicare plans in 140 counties and exits Wyoming
UnitedHealthcare plans to discontinue some Medicare Advantage products in 140 counties and exit Wyoming’s Medicare Advantage and Part D markets in 2027, affecting about 390,000 members. The company cited funding pressures, rising medical and drug costs, and increased utilization. Affected members can select new coverage during the enrollment period, while the company is reducing PPO offerings and emphasizing HMO and Special Needs Plans.
Investors and commentators assess UnitedHealth’s margin recovery
Commentary cited elevated commercial utilization, provider billing and arbitration pressures, Medicare Advantage rating uncertainty and policy concerns as factors weighing on UnitedHealth. Other pieces pointed to improving margins, AI investment and a recovery in the shares after better-than-expected results. The articles also discussed institutional holdings, valuation estimates and risks to the company’s recovery; they did not report a new operational change.
Warren calls for UnitedHealth to separate care providers from insurance
Elizabeth Warren criticized the Justice Department’s approval of UnitedHealth’s $3.3 billion Amedisys acquisition and backed legislation requiring divestitures by companies that own pharmacy benefit managers and pharmacies. The deal’s settlement required divestiture of 164 home health and hospice locations across 19 states. Warren’s proposed legislation has not advanced, and coverage noted that passage faces obstacles; Mark Cuban also warned that AI could disrupt large healthcare companies.
UnitedHealth approves quarterly dividend of $2.32 per share
UnitedHealth approved a quarterly dividend of $2.32 per share, payable December 15, 2026. The article also noted that the company raised its 2026 adjusted EPS guidance to at least $20.50 after third-quarter adjusted EPS of about $4.69. It described institutional buying and AI-driven cost controls as supportive sentiment factors, while noting regulatory, Medicare Advantage and legal risks.
UnitedHealthcare removes prior authorization for more than 2,000 pediatric services
The changes cover services including imaging, sleep studies, cancer treatment and orthopedic care across commercial, Individual Exchange and Community plans where state law permits. UnitedHealthcare said the changes would cut pediatric authorization volume by nearly two-thirds. Some complex services and state-regulated care will still require authorization, as part of broader efforts to simplify prior authorizations and reduce administrative burden.
Optum Insight expands AI tools as revenue grows 2.7%
Optum Insight is investing in AI to automate healthcare administration and expand its technology offerings. Operating earnings increased to $3.6 billion and margin expanded 150 basis points in the first nine months of 2026. Optum Integrity One had 15 implemented clients and 24 more in implementation, while investment costs and product rationalization may limit near-term growth.